Aquestive Therapeutics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • AQST
  • 1d0.77%
  • 1w-3.67%
  • 1m-35.30%
  • 1y210.24%
ATH
  • ATH Price$18.96
  • ATH Date2018-09-07
  • % since ATH-79.22%
  • % to ATH381.22%
ATL
  • ATL Price$0.63
  • ATL Date2022-07-01
  • % from ATL525.40%
  • Last Low Price$0.63
  • Last Low Date2022-07-01
  • % From Last Low525.40%
IPO
  • IPO Price$15.05
  • % Current ROI USD-73.82%
  • ATH Price$18.96
  • % ROI ATH 300,952.38%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="AQST"]

Key Data [addtoany]

Current price $3.94
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $4.1/$3.83
Volume 1,341,474.00
Previous Close $3.91
52 Week High/Low $6.23/$1.15
Market Cap 351,774,528.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.3
Annualized Dividend $0
$3.94
[addtoany]

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.
The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
The company’s proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly.
Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity